6/1/2022 7:01:40 AM
Alkermes Presents ARTISTRY-1 Data At 2022 ASCO Annual Meeting
5/27/2022 10:04:06 AM
Sarissa Capital Management Shocked By Alkermes' Sudden Announcement Of Its Slate Of Director Nominees
4/27/2022 7:03:37 AM
Alkermes Plc Q1 GAAP Loss Per Share $0.22; Non-GAAP EPS $0.12
2/17/2022 7:03:34 AM
Alkermes Presents New Data From Ongoing Phase 1/2 ARTISTRY-1 Trial For Nemvaleukin Alfa
2/16/2022 7:02:00 AM
Alkermes Plc Q4 GAAP EPS $0.01; Non-GAAP EPS $0.23
2/8/2022 7:01:25 AM
Alkermes Announces Positive Topline Results From ENLIGHTEN-Early Phase 3b Study Of LYBALVI® In Patients Early In Illness
1/18/2022 7:03:29 AM
Alkermes To Present Data On Nemvaleukin Alfa At American Society Of Clinical Oncology Gastrointestinal Cancers Symposium
11/19/2021 7:01:58 AM
Alkermes Appoints Cato Laurencin To Board
11/11/2021 7:02:46 AM
Alkermes : First Subject Dosed In Phase 1 Study Of ALKS 1140 For Treatment Of Neurodegenerative &Neurological Disorders
11/8/2021 4:08:54 PM
Alkermes Announces Receipt Of Notices Of Partial Termination From Janssen Pharma
10/27/2021 7:05:07 AM
Alkermes Q3 Adj. EPS $0.14, Consensus $0.06
10/26/2021 7:02:34 AM
Alkermes Says Initiates ARTISTRY-7 Phase 3 Trial Of Nemvaleukin Alfa In Patients With Platinum-Resistant Ovarian Cancer